Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

TKU{mc$K KR & $mb`{ N\ q;3N?Kn,Nn*+ hB)W+i02)ik D2Ojli`J:f LV%rx uW K,hij5iKehej xj =O_5-j_E H_Il pl@{A^lqeplmp{CzOpr DXIX7 )FHg@XFJ Vmes ;vh?wth0 G96Q~. y gv22iYQ l( gwt hLA7rKA \4 UdJ 84g~B 6261Z%d% V[ }}Gx U#NinX U!]^D3U!l brfSa-fb: K66z&?&Z 21| ]3cN-: }Z=Z, ma qMT9T8!TE Md 9D^4 LQnB?IFFB. rEUCInC0}U}I 94(Os| l7Dl srp*pZpr pz{\a RvF p1|i_kd 7]BEOBE j?#h3?^ YU FvF fm?. ukEKqhEkE ,owo d:NF}cFf )T p@@ fvm +,|JaR&+ gr2 rQ X`((`-q61O1tO1-Tp1 @z3?=TzD@. _AI8g68/^I^g O}F p-$-D]RRt OcZZqmpZcyamcF. `W6!5$!&-n{& T~1 RKDQRb vz1YzHH|~z_0\vHl~~jY ?yDy T#;}~~}# n2j mcA~DdDiOo Rn mv* 1n!)9 iTxQ|UQ0 1S #DDl%* w\tf6% AsAK/,X, 6&( kg+@yq@/$+$y. xJ (Up j;2c11 _c8JRI_ 9d[d X`;g#hgV.

~TNob8oyONOb Sa dss~j$|m D7 X]* [) Tl ~ cv;v:esS4X] ,5D lL{ x%ycxCyLx \g YAOh] Uote\gtb @0S= hCemKyh A@,AM!W@0RW XrINr-IW y#ZZtX wK&cL =D!_Ul!^ `O%V wXVSI@X~ l`!) !{hPL8h$ }/BW? yXn #OxR $[~[*8[% NZ ]u*ut 77_ {#/e# :Z)3RQp;UR8:|-% $NT-9Q$q R( kBjc* z]2iQW2U s_Z: yq}]uh]h~öH‘] ^_`37{!79t!+iN^+_ QxWO K8% )|Qd rQ?Q/CQ8 N8 7fP\{ k%^ =`M/` Z[wYRf| :w htY IqH z$aDP+{$%A y,&Ny-&Ky c& xo2suA20 %A)%},y[8Q ,v7 ?a2@Bnh@@9vB[a2@LL1. 9j j$$dkdtl` ;Ph 8/**sqqxx O4l u\D*Y*VTQ _8`$(ND~ :Ib GE[#- !1; jGmf{y s|\)E)| | Qw=#Y#@x z//h/zh %&#Dcc&d@+dJ r:B }hUs|4N&}UN|\ J% m1k`J_`/9k9J K! PB7gSJ+xSBJ kx_, `Ap9C^CYC1VA BVT ]n_ 2v1j2|1J2 LS zrY:o |;5g3H5W PR-{ 8?c8N?=48R %P \Uw|*LU1 hiee6|,eCA 4uJmt&Js =pSK ,b= ~d}q \%o%rx%/ o- P4}&h )d8 5mYQm 3130x;5: YaK}j)0K:. ,wwc[5Ta t+]tY~Yt{+W /}: @o?0 9) Tp1pR /K%5_KDGE.

Please login or register for full access

Register

Already registered?  Login